Human Prostate Cancer Xenograft Study Complete

LaZure Scientific, Inc. recently announced the completion of a non-clinical study to evaluate the effect of its proprietary Low Dose Alternating Electric Current (LDAEC) therapy on human prostate cancer xenografts in immune deficient mice.
The study included over ninety mice implanted with human prostate cancer tumors that received treatment with the LDAEC technology. Results from the study indicated that the LDAEC therapy was effective in eliminating xenograft tumor cells exposed to the LDAEC treatment, while at the same time leaving healthy normal tissue such as nerves and blood vessels within and around the treatment space unharmed.
The LaZure Low Dose Alternating Electric Current (LDAEC) technology is an electrosurgical instrument system that delivers a low-intensity, intermediate frequency alternating electric field to a desired target tissue area, such as the prostate, to preferentially destroy cancerous tissue and lesions while limiting treatment related side effects by sparing vital tissue types including smooth muscle, nerves, and large blood vessels. Observations from non-clinical studies suggest that LDAEC may hold promise as novel therapy for certain cancer types.
LDAEC therapy has not yet been evaluated in humans and has not received regulatory clearance or approval from the FDA.

Sorry, comments are closed for this post.